Soleil Boughton Sells 268,932 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 268,932 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $27.75, for a total value of $7,462,863.00. Following the completion of the sale, the insider now owns 169,803 shares of the company’s stock, valued at approximately $4,712,033.25. This trade represents a 61.30 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, November 26th, Soleil Boughton sold 2,343 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.90, for a total value of $70,055.70.
• On Tuesday, October 29th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The shares were sold at an average price of $23.16, for a total value of $54,171.24.
• On Tuesday, October 15th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.41, for a total transaction of $47,738.99.

Hims & Hers Health Stock Up 2.6 %

HIMS stock traded up $0.71 during trading on Tuesday, hitting $27.61. The company had a trading volume of 10,914,906 shares, compared to its average volume of 9,194,688. The firm has a market capitalization of $6.03 billion, a P/E ratio of 62.75 and a beta of 1.31. The company has a 50 day simple moving average of $26.73 and a 200-day simple moving average of $21.53. Hims & Hers Health, Inc. has a 52-week low of $8.14 and a 52-week high of $35.02.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.26. The company had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Hims & Hers Health’s revenue was up 77.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.04) earnings per share. Sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of recent analyst reports. Canaccord Genuity Group boosted their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, December 2nd. Deutsche Bank Aktiengesellschaft boosted their price target on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Piper Sandler boosted their price target on Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a research note on Monday. TD Cowen restated a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Finally, Needham & Company LLC boosted their price target on Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $24.80.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC grew its position in shares of Hims & Hers Health by 2,173.7% in the 4th quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock worth $54,000 after buying an additional 2,152 shares during the last quarter. Quest Partners LLC grew its holdings in Hims & Hers Health by 5,944.1% in the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after purchasing an additional 3,507 shares during the last quarter. CWM LLC increased its position in shares of Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after purchasing an additional 1,054 shares in the last quarter. Van ECK Associates Corp purchased a new stake in shares of Hims & Hers Health during the 2nd quarter valued at $111,000. Finally, Quarry LP raised its stake in Hims & Hers Health by 91.0% in the third quarter. Quarry LP now owns 6,113 shares of the company’s stock valued at $113,000 after buying an additional 2,913 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.